News

Rating 0 - Votos (0)

139 visitas

publicado el 14/09/2022

The first zebrafish laboratory for biomedical purposes is inaugurated in Havana.

With the purpose of studying multiple neurological diseases, this Tuesday the first zebrafish laboratory in the country was inaugurated at the Drug Research and Development Center (Cidem), in this capital.

A report from the Cuban News Agency, informs that Yanier Núñez Figueredo, director of the institution's Experimental Neuropharmacology Laboratory, explained that this species shares 75 percent (%) of the genes with the human being and up to 85% in disease conditions, so it has been of great interest to the scientific community in the investigation of new drugs in early stages.

During a tour of the new facility and in the presence of Eduardo Martínez Díaz, president of the BioCubaFarma Business Group, the also doctor in Pharmaceutical Sciences stated that Cidem works on the line of dementia, ischemia, Parkinson's and Alzheimer's, and will simulate these diseases in fish to then evaluate their response to the different drugs.

The Center for the State Control of Medicines, Equipment and Medical Devices, a Cuban regulatory authority, requires that products be evaluated in the preclinical stage in two types of species and these animals are widely used worldwide, the researcher assured.

Alejandro Saúl Padrón Yaquis, general director of Cidem, pointed out that with the laboratory they have the purpose of contributing to the preclinical research of the different BioCubaFarma products and that the transition to the clinical stage be as fast as possible and with the necessary scientific rigor.

In relation to neurological diseases, Cidem collaborates with the Faculty of Chemistry of the University of Havana and other entities of the Business Group in various projects, including the development of an innovative molecule called JM-20.

The doctor of sciences specified that in rodents the molecule has preclinical data that demonstrates good results, and from the creation of the laboratory this evidence will have support in zebrafish, which will make it possible to start clinical trials in dementia in 2023.

The laboratory has rooms for the reproduction of the species, their growth during the five months required to start the experiments and the behavior area where, based on the use of other types of fish, they analyze the behavior of the animals.

Cidem is a scientific institution, belonging to BioCubaFarma, dedicated to the research and development of generic medicines, natural products, advanced technologies and diagnostic means.

Your opinion matters
Leave your comments

When you make your comment, note that

  • You must not use offensive words.
  • It must be in relation to the topic.
  • It must published comply with the above policies to be published.




0 comments inserted